| Market Capitalization (Millions $) |
474 |
| Shares
Outstanding (Millions) |
112 |
| Employees |
17 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-4 |
| Cash Flow (TTM) (Millions $) |
6 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Relmada Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing novel therapies for the treatment of central nervous system (CNS) disorders. The company was founded in 2004 and is headquartered in New York, NY.
Relmada's lead product candidate is dextromethadone (d-Methadone), which is a new chemical entity designed to treat chronic pain in a way that avoids the potential for abuse and addiction. It is currently undergoing phase III clinical trials for the treatment of neuropathic pain associated with complex regional pain syndrome (CRPS). In addition, the company is developing other drug candidates aimed at addressing other CNS disorders such as depression, anxiety, and addiction.
Relmadaes approach to drug development focuses on optimizing the pharmacology of existing drugs rather than designing entirely new ones. This approach reduces the overall development time and costs while allowing the company to leverage existing clinical data and expertise.
The companyes drug development programs are based on intellectual property licensed from the University of Chicago, the Companyes co-founders, and from third-party licensors. Relmadaes proprietary technological platform enables the development of new chemical entities and the optimization of existing drugs' pharmacology.
Relmadaes team of experienced scientists, executives, and advisors have a track record of successful drug development and commercialization. The Companyes management team includes an Executive Chairman, CEO, and COO, and the board of directors includes high-level executives from the pharmaceutical industry.
In summary, Relmada Therapeutics Inc. is a clinical stage biopharmaceutical company that focuses on developing novel therapies for the treatment of CNS disorders, leveraging the optimization of existing drugs and a proprietary technological platform. The company's main drug candidate is d-Methadone, which is currently in Phase III clinical trials for the treatment of neuropathic pain associated with CRPS.
Company Address: 2222 Ponce de Leon Coral Gables 33134 FL
Company Phone Number: 629-1376 Stock Exchange / Ticker: NASDAQ RLMD
|
4.62% 